Peripheral T-Cell Lymphomas (PTCL) - Pipeline Review, H2 2016

  • ID: 3895088
  • Report
  • 246 pages
  • Global Markets Direct
1 of 6

FEATURED COMPANIES

  • AB Science SA
  • arGEN-X BV
  • Boehringer Ingelheim GmbH
  • CerRx, Inc.
  • Genosco
  • Japan Tobacco Inc.
  • MORE
Peripheral T-Cell Lymphomas (PTCL) - Pipeline Review, H2 2016

Summary

‘Peripheral T-Cell Lymphomas (PTCL) - Pipeline Review, H2 2016’, provides an overview of the Peripheral T-Cell Lymphomas (PTCL) pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Peripheral T-Cell Lymphomas (PTCL), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Peripheral T-Cell Lymphomas (PTCL) and features dormant and discontinued projects.

The report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape of Peripheral T-Cell Lymphomas (PTCL)
- The report reviews pipeline therapeutics for Peripheral T-Cell Lymphomas (PTCL) by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved Peripheral T-Cell Lymphomas (PTCL) therapeutics and enlists all their major and minor projects
- The report assesses Peripheral T-Cell Lymphomas (PTCL) therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Peripheral T-Cell Lymphomas (PTCL)

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Peripheral T-Cell Lymphomas (PTCL)
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Peripheral T-Cell Lymphomas (PTCL) pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
READ MORE
Note: Product cover images may vary from those shown
2 of 6

FEATURED COMPANIES

  • AB Science SA
  • arGEN-X BV
  • Boehringer Ingelheim GmbH
  • CerRx, Inc.
  • Genosco
  • Japan Tobacco Inc.
  • MORE
List of Tables

List of Figures

Introduction

Report Coverage

Peripheral T-Cell Lymphomas (PTCL) Overview

Therapeutics Development

Pipeline Products for Peripheral T-Cell Lymphomas (PTCL) - Overview

Peripheral T-Cell Lymphomas (PTCL) - Therapeutics under Development by Companies

Peripheral T-Cell Lymphomas (PTCL) - Pipeline Products Glance

Late Stage Products

Clinical Stage Products

Early Stage Products

Peripheral T-Cell Lymphomas (PTCL) - Products under Development by Companies

Peripheral T-Cell Lymphomas (PTCL) - Companies Involved in Therapeutics Development

AB Science SA

Affimed GmbH

arGEN-X BV

Bayer AG

Boehringer Ingelheim GmbH

Celgene Corporation

CerRx, Inc.

Chipscreen Biosciences Ltd

CSPC Pharmaceutical Group Limited

Eisai Co., Ltd.

Genosco

Incyte Corporation

Japan Tobacco Inc.

Johnson & Johnson

Mundipharma International Ltd

Ono Pharmaceutical Co., Ltd.

Onxeo SA

Pfizer Inc.

Pharma Mar, S.A.

Portola Pharmaceuticals, Inc.

Rhizen Pharmaceuticals S.A.

Seattle Genetics, Inc.

Solasia Pharma K.K.

Spectrum Pharmaceuticals, Inc.

Peripheral T-Cell Lymphomas (PTCL) - Therapeutics Assessment

Assessment by Monotherapy Products

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Drug Profiles

AFM-13 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ARGX-110 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

belinostat - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

brentuximab vedotin - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Cellular Immunotherapy to Target CD7 for Relapsed and Refractory Leukemia and Lymphoma - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

cerdulatinib - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

copanlisib hydrochloride - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

darinaparsin - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

denileukin diftitox - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

enasidenib - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

fenretinide - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

forodesine hydrochloride - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ICG-122 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

lenalidomide - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

masitinib - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

MEDI-570 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

mitoxantrone hydrochloride - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

nivolumab - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

NL-101 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

plitidepsin - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

pralatrexate - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

romidepsin - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

RP-6530 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ruxolitinib phosphate - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

SH-7129 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule to Inhibit SYK for Diffuse Large B-Cell Lymphoma and Peripheral T-Cell Lymphoma - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

temsirolimus - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

TGR-1202 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

tipifarnib - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

tucidinostat - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

volasertib trihydrochloride - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Peripheral T-Cell Lymphomas (PTCL) - Dormant Projects

Peripheral T-Cell Lymphomas (PTCL) - Discontinued Products

Peripheral T-Cell Lymphomas (PTCL) - Product Development Milestones

Featured News & Press Releases

Aug 16, 2016: CAR T-cells Targeting the CD4 Protein Granted FDA Orphan Drug Designation

Aug 11, 2016: CAR T-cells Targeting the CD4 Protein Granted Orphan Drug Designation for the Treatment of Peripheral T-cell Lymphoma

Jun 14, 2016: PharmaMar Announces the Start of a Pivotal Study With plitidepsin in angioimmunoblastic T-cell lymphoma

Jun 02, 2016: Onxeo Announces Development of Beleodaq Oral Formulation Opening New Opportunities for Its HDAC Inhibitor

Mar 28, 2016: Solasia Initiates Phase 2 Study of Darinaparsin (SP-02) for Peripheral T-Cell Lymphoma

Dec 22, 2015: Huya Bioscience International Announces Orphan Drug Designation For HBI-8000 In Japan

Dec 07, 2015: Seattle Genetics Highlights ADCETRIS Data Presentations in Frontline Non-Hodgkin Lymphoma at ASH 2015

Dec 06, 2015: Spectrum Pharmaceuticals and Onxeo Announce Complete Response in 67% of Patients with Peripheral T-Cell Lymphoma in Combination of Belinostat and Standard CHOP

Nov 09, 2015: Onxeo Reports Initial Results of Phase 1 Trial Evaluating Belinostat in Combination with CHOP in Peripheral T-cell Lymphoma

Sep 30, 2015: Kura Oncology Initiates Phase 2 Study of Tipifarnib in Peripheral T-cell Lymphoma

Jun 23, 2015: Beleodaq (belinostat) pivotal BELIEF study results published in the Journal of Clinical Oncology

May 27, 2015: AB Science: Phase 2 with masitinib in peripheral T-cell lymphoma accelerated into phase 3

Jan 12, 2015: HUYA Bioscience International Announces Regulatory Approval Of Chidamide, The First Selective HDAC Inhibitor In China

Jan 09, 2015: Chipscreen Biosciences Announces CFDA Approval of Chidamide (Epidaza) for PTCLs in China

Jan 08, 2015: HUYA Bioscience International Is The First To Leverage Tripartite Cooperation

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

Number of Products under Development for Peripheral T-Cell Lymphomas (PTCL), H2 2016

Number of Products under Development by Companies, H2 2016

Number of Products under Development by Companies, H2 2016 (Contd..1)

Comparative Analysis by Late Stage Development, H2 2016

Comparative Analysis by Clinical Stage Development, H2 2016

Comparative Analysis by Early Stage Development, H2 2016

Products under Development by Companies, H2 2016

Products under Development by Companies, H2 2016 (Contd..1)

Products under Development by Companies, H2 2016 (Contd..2)

Peripheral T-Cell Lymphomas (PTCL) - Pipeline by AB Science SA, H2 2016

Peripheral T-Cell Lymphomas (PTCL) - Pipeline by Affimed GmbH , H2 2016

Peripheral T-Cell Lymphomas (PTCL) - Pipeline by arGEN-X BV, H2 2016

Peripheral T-Cell Lymphomas (PTCL) - Pipeline by Bayer AG, H2 2016

Peripheral T-Cell Lymphomas (PTCL) - Pipeline by Boehringer Ingelheim GmbH, H2 2016

Peripheral T-Cell Lymphomas (PTCL) - Pipeline by Celgene Corporation, H2 2016

Peripheral T-Cell Lymphomas (PTCL) - Pipeline by CerRx, Inc., H2 2016

Peripheral T-Cell Lymphomas (PTCL) - Pipeline by Chipscreen Biosciences Ltd, H2 2016

Peripheral T-Cell Lymphomas (PTCL) - Pipeline by CSPC Pharmaceutical Group Limited, H2 2016

Peripheral T-Cell Lymphomas (PTCL) - Pipeline by Eisai Co., Ltd., H2 2016

Peripheral T-Cell Lymphomas (PTCL) - Pipeline by Genosco, H2 2016

Peripheral T-Cell Lymphomas (PTCL) - Pipeline by Incyte Corporation, H2 2016

Peripheral T-Cell Lymphomas (PTCL) - Pipeline by Japan Tobacco Inc., H2 2016

Peripheral T-Cell Lymphomas (PTCL) - Pipeline by Johnson & Johnson, H2 2016

Peripheral T-Cell Lymphomas (PTCL) - Pipeline by Mundipharma International Ltd, H2 2016

Peripheral T-Cell Lymphomas (PTCL) - Pipeline by Ono Pharmaceutical Co., Ltd., H2 2016

Peripheral T-Cell Lymphomas (PTCL) - Pipeline by Onxeo SA, H2 2016

Peripheral T-Cell Lymphomas (PTCL) - Pipeline by Pfizer Inc., H2 2016

Peripheral T-Cell Lymphomas (PTCL) - Pipeline by Pharma Mar, S.A., H2 2016

Peripheral T-Cell Lymphomas (PTCL) - Pipeline by Portola Pharmaceuticals, Inc., H2 2016

Peripheral T-Cell Lymphomas (PTCL) - Pipeline by Rhizen Pharmaceuticals S.A., H2 2016

Peripheral T-Cell Lymphomas (PTCL) - Pipeline by Seattle Genetics, Inc., H2 2016

Peripheral T-Cell Lymphomas (PTCL) - Pipeline by Solasia Pharma K.K., H2 2016

Peripheral T-Cell Lymphomas (PTCL) - Pipeline by Spectrum Pharmaceuticals, Inc., H2 2016

Assessment by Monotherapy Products, H2 2016

Number of Products by Stage and Target, H2 2016

Number of Products by Stage and Mechanism of Action, H2 2016

Number of Products by Stage and Route of Administration, H2 2016

Number of Products by Stage and Molecule Type, H2 2016

Peripheral T-Cell Lymphomas (PTCL) - Dormant Projects, H2 2016

Peripheral T-Cell Lymphomas (PTCL) - Discontinued Products, H2 2016 232List of Figures

Number of Products under Development for Peripheral T-Cell Lymphomas (PTCL), H2 2016

Number of Products under Development by Companies, H2 2016

Comparative Analysis by Clinical Stage Development, H2 2016

Comparative Analysis by Early Stage Products, H2 2016

Assessment by Monotherapy Products, H2 2016

Number of Products by Top 10 Targets, H2 2016

Number of Products by Stage and Top 10 Targets, H2 2016

Number of Products by Top 10 Mechanism of Actions, H2 2016

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016

Number of Products by Routes of Administration, H2 2016

Number of Products by Stage and Routes of Administration, H2 2016

Number of Products by Molecule Types, H2 2016

Number of Products by Stage and Molecule Types, H2 2016
Note: Product cover images may vary from those shown
3 of 6

Loading
LOADING...

4 of 6

FEATURED COMPANIES

  • AB Science SA
  • arGEN-X BV
  • Boehringer Ingelheim GmbH
  • CerRx, Inc.
  • Genosco
  • Japan Tobacco Inc.
  • MORE
Peripheral T-Cell Lymphomas (PTCL) pipeline therapeutics constitutes close to 31 molecules. Out of which approximately 31 molecules are developed by Companies. Our latest report Peripheral T-Cell Lymphomas (PTCL) – Pipeline Review, H2 2016, outlays comprehensive information on the therapeutics under development for Peripheral T-Cell Lymphomas (PTCL), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type.

Peripheral T-Cell Lymphomas (PTCL) Peripheral T-cell lymphoma (PTCL) is a rare and often aggressive (fast-growing) cancer that develops from white blood cells called T-lymphocytes, or T-cells. T-cells are an important part of the immune system; they help the body to fight infection. In cases when these cells start to grow too quickly and resist dying, they can accumulate in the body. Symptoms may include fatigue, a painless swelling in the neck, armpit or groin (due to an enlarged lymph node), night sweats and rash. The molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 2, 19, 5, 4 and 1 respectively.

Furthermore, this report also reviews of key players involved in therapeutic development for Peripheral T-Cell Lymphomas (PTCL) and features dormant and discontinued projects. Driven by data built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.
Note: Product cover images may vary from those shown
5 of 6
AB Science SA
Affimed GmbH
arGEN-X BV
Bayer AG
Boehringer Ingelheim GmbH
Celgene Corporation
CerRx, Inc.
Chipscreen Biosciences Ltd
CSPC Pharmaceutical Group Limited
Eisai Co., Ltd.
Genosco
Incyte Corporation
Japan Tobacco Inc.
Johnson & Johnson
Mundipharma International Ltd
Ono Pharmaceutical Co., Ltd.
Onxeo SA
Pfizer Inc.
Pharma Mar, S.A.
Portola Pharmaceuticals, Inc.
Rhizen Pharmaceuticals S.A.
Seattle Genetics, Inc.
Solasia Pharma K.K.
Spectrum Pharmaceuticals, Inc.
Note: Product cover images may vary from those shown
6 of 6
Note: Product cover images may vary from those shown
Adroll
adroll